A genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy

dc.contributor.authorPuangmalai, Nicha
dc.contributor.authorSomani, Alyma
dc.contributor.authorThangnipon, Wipawan
dc.contributor.authorBallard, Clive
dc.contributor.authorBroadstock, Martin
dc.date.accessioned2016-06-06T13:39:03Z
dc.date.available2016-06-06T13:39:03Z
dc.date.issued2015-10-21
dc.description.abstractAmyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer’s disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.en
dc.identifier.doi10.17179/excli2015-560
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/35056
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-17104
dc.language.isoen
dc.relation.ispartofseriesEXCLI Journal;Vol. 14, 2015en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAlzheimer’s diseaseen
dc.subjectcell viabilityen
dc.subjectCTX0E03 cell lineen
dc.subjectneural stem cellen
dc.subjectokadaic aciden
dc.subjectoligomeric amyloid-βen
dc.subject.ddc610
dc.titleA genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapyen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.zdberstkatid2132560-1

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Thangnipon_21102015_proof.pdf
Size:
428.96 KB
Format:
Adobe Portable Document Format
Description:
DNB
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.12 KB
Format:
Item-specific license agreed upon to submission
Description: